Great Britain

Novavax vaccine 90% effective in protecting against moderate and severe Covid, trial results suggest

Vaccine maker Novavax has said its shot was highly effective against Covid-19 and also protected against variants in a large, late-stage study in the US and Mexico.

The vaccine was about 90% effective overall and preliminary data showed it was safe, the company said.

The company says it plans to seek authorisation for the jabs in the US, Europe and elsewhere by the end of September and be able to produce up to 100 million doses a month by then.

“Many of our first doses will go to ... low and middle-income countries, and that was the goal to begin with,” Novavax chief executive Stanley Erck said today.

Less than 1 per cent of people in the developing world have had one Covid-19 vaccine dose, according to Our World In Data.

The study undertaken by the company involved nearly 30,000 people aged 18 and above in the US and Mexico. Two-thirds received two doses of the vaccine, three weeks apart, and the rest got dummy shots.

There were 77 cases of Covid-19 in the group that got the vaccine and the rest were in volunteers who received dummy shots.

None in the vaccine group had moderate or severe disease, compared to 14 in the placebo group.

More to follow...

Football news:

Milan can give Caldara on loan to Torino, Sampdoria or Venice
Manchester United midfielder Pereira is Interesting for Fenerbahce. The Turkish club is not ready to pay 25 million euros for him
Pulisic on the new season: Chelsea saw that they can fight with the top teams. Everything is possible
Real Madrid can sell Edegor for 50 million euros if Martin insists on leaving
Sebastian Driussi: I am glad to continue my career in MLS. It is an honor to play for Austin
Tottenham is ready to pay 40-45 million euros for Romero. Barcelona did not make any offers to Atalanta
Giorgio Chiellini: There will be no symbol of the Italian champions on the Juve shirt-this motivates